SGAM
VNDA icon

Smith Group Asset Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Smith Group Asset Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-18,020
Closed -$287K – 478
2016
Q4 		$287K Sell
18,020
-2,910
-14% -$46.8K 0.01% 228
2016
Q3 		$348K Buy
+20,930
New +$282K 0.01% 210
2014
Q4 		– Sell
-104,761
Closed -$1.09M – 446
2014
Q3 		$1.09M Sell
104,761
-350
-0.3% -$4.59K 0.04% 174
2014
Q2 		$1.7M Sell
105,111
-4,763
-4% -$63.4K 0.06% 163
2014
Q1 		$1.78M Sell
109,874
-649
-0.6% -$9.23K 0.07% 163
2013
Q4 		$1.37M Buy
+110,523
New +$1.11M 0.05% 170

Other funds holding VNDA

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Smith Group Asset Management's VNDA Position: Q1 2017 in Review

Smith Group Asset Management sold out of Vanda Pharmaceuticals (VNDA) in Q1 2017, closing a stake of 18,020 shares — an estimated $287K sold.

Smith Group Asset Management first reported a position in VNDA in Q4 2013 and held it in 6 quarters. The position peaked at $1.78M in Q1 2014. 136 funds tracked by Wall St. Rank hold VNDA as of Q1 2017.

  • Smith Group Asset Management reported no remaining Vanda Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Smith Group Asset Management sold 18,020 Vanda Pharmaceuticals shares in Q1 2017, an estimated $287K.
  • Smith Group Asset Management first reported a position in Vanda Pharmaceuticals in Q4 2013 and held it in 6 quarters.
  • Smith Group Asset Management's Vanda Pharmaceuticals position peaked at $1.78M in Q1 2014.
  • 136 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2017.

Based on Smith Group Asset Management's 13F filing for Q1 2017, filed 4 May 2017.